Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Inquiry Memorial
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • The Inquiry Report
    • Additional Compensation Report
    • First Interim Report
    • Second Interim Report
    • Compensation Framework Study
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Support and FAQs
    • NHS Psychological Support
    • Support Groups
    • Infected Blood Support Schemes
    • Hepatitis C Testing
  • Contact us
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Subscribe to Search results

A witness to the Inquiry was told they had Hepatitis C roughly 40 years after they were first infected.

Published on: 30 September, 2024

Rosamund Cooper accidentally discovered her Hepatitis C diagnosis when it was casually mentioned by a doctor during a pre-operative chat.

Published on: 30 September, 2024

Dr Jones stated "John Craske tells me that they will hopefully soon be in a position to test all our patients for HTLV3 antibody and the families know that. They alsoknow that they will be told the results."

Published on: 30 September, 2024

The small prospective study of cryoprecipitate treatment showed no evidence of infection with hepatitis or HIV viruses after careful follow up of each patient for one year.

Published on: 30 September, 2024

Study on the inactivation of HTLV-III/LAV during plasma fractionation whose results indicated that steps in large scale plasma fractionation, especially ethanol at -5C and low pH, reduced the risk of plasma products being infectious should the source material be contaminated by HTLV-III/LAV.

Published on: 30 September, 2024

Scottish patients with haemophilia, most of whom had received no American factor VIII concentrate for over two years, were found to have immunological abnormalities. This included a reduced proportion of T helper cells an increased proportion of T suppressor cells, and a reduced response to eoncanavilin A.

Published on: 30 September, 2024

In the summer of 1985 two meetings regarding HIV and AIDs were held at Pendlebury that called for the attendance of parents of children with bleeding disorders.

Published on: 30 September, 2024

Dr Anna Pettigrew took up post as a part-time clinical assistant at the Royal Hospital for Sick Children.

Published on: 30 September, 2024

Dr Pettigrew recollected that newly diagnosed patients or those with mild haemophilia were treated with cryoprecipitate and those on home therapy or frequent attending patients were treated with concentrate.

Published on: 30 September, 2024

Dr Pettigrew recalled commercial product was more user friendly and dissolved quicker.

Published on: 30 September, 2024

Parents often administered home therapy which was preferred.

Published on: 30 September, 2024

Home therapy and prophylactic therapy were introduced by Dr Willoughby for psychological and clinical reasons.

Published on: 30 September, 2024

Dr Pettigrew viewed that all clinical staff acted in what they thought to be in the best interests of their patients, including Dr Willoughby (who instituted home therapy with Factor VIII concentrates.

Published on: 30 September, 2024

Cryoprecipitate, although less convenient to use, was not impracticable for home treatment despite what the opinion at Yorkhill hospital was.

Published on: 30 September, 2024

Glasgow Yorkhill Haemophilia Centre's annual returns showed substantial but decreasing use of commercial compared to PFC concentrates.

Published on: 30 September, 2024

RHSC annual return showed 62,315 units of commercial concentrate was used for haemophilia treatment.

Published on: 30 September, 2024

RHSC annual return showed 123,998 units of commercial concentrate was used for haemophilia treatment.

Published on: 30 September, 2024

RHSC annual return showed 354,276 units of commercial concentrate was used for haemophilia treatment.

Published on: 30 September, 2024

RHSC annual return showed 682,732 units of commercial concentrate was used for haemophilia treatment.

Published on: 30 September, 2024

RHSC annual return showed 629,697 units of commercial concentrate was used for haemophilia treatment.

Published on: 30 September, 2024

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 2121
  • Page 2122
  • Page 2123
  • Page 2124
  • Current page 2125
  • Page 2126
  • Page 2127
  • Page 2128
  • Page 2129
  • …
  • Next page Next
  • Last page Last

Inquiry

  • Home
  • About
  • Approach
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.